Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel(University of Duisburg-Essen), Frank Jessen(German Center for Neurodegenerative Diseases), Michael Jacoby(Mercy Clinic Neurology), Judith Alferink(University of Münster), Yaroslav Winter(Philipps University of Marburg), Julius Popp(University of Lausanne), Kaj Blennow(Sahlgrenska University Hospital), Jerome Goldstein, Peter Bartenstein(LMU Klinikum), Stefan Förster(German Center for Neurodegenerative Diseases), Ralph Richter(Leibniz Institute for Research on Society and Space), Katharina Büerger(German Center for Neurodegenerative Diseases), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Axel Rominger(University Hospital of Bern), Stefan Haag(Octapharma (Switzerland)), Markus Otto(University Hospital in Halle), Martin R. Farlow(MRC Laboratory of Molecular Biology), Jan‐Philipp Bach(Philipps University of Marburg), Isaac Melamed, James C. Stevens(FWRadiology), Stefan Wietek(Octapharma (Austria)), Piero Antuono(Medical College of Wisconsin), Jens Wiltfang(German Center for Neurodegenerative Diseases)
Cited by 185
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k